# US 2026/0060706 A1 · Method for the treatment of thromboembolism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060706 A1
- Document ID: US20260060706A1
- Status: Published application
- Kind: A1
- Application number: 19/379,323
- Filed: 2025-11-04
- Published: 2026-03-05
- Earliest claimed: 2017-01-24
- Assignees: Boston Scientific Scimed, Inc.
- Applicants: Boston Scientific Scimed, Inc.
- Inventors: Lynn Gourley Allen
- Web page: https://patentgrep.com/patent/US20260060706A1

## CPC

- A61B 17/2202: {the ultrasound transducer being inside patient's body at the distal end of the catheter}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61M 37/0092: {using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61B 2017/22084: {stone- or thrombus-dissolving}
- A61B 2017/22088: {ultrasound absorbing, drug activated by ultrasound}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for the treatment of thromboembolism comprising administering a thrombolytic agent directly to the thromboembolism in the presence of ultrasound. The total dose of thrombolytic agent administered is between 1 and 12 mg and the time over which the total dose is delivered is less than 15 hours.

## Claims

### Claim 1

A thrombolytic agent for use in a treatment of a thromboembolism, wherein the treatment comprises administering the thrombolytic agent directly to the thromboembolism in the presence of ultrasound, wherein a total dose of the thrombolytic agent is between 0.1 and 12 mg and is administered as one or more small bolus doses of between 0.1 and 0.9 mg, and the time over which the total dose of the thrombolytic agent is delivered is 6 hours or less.

### Claim 2 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the total dose of the thrombolytic agent administered is 0.2 to 10 mg.

### Claim 3 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the total dose of the thrombolytic agent administered is 0.2 to 6 mg.

### Claim 4 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the total dose of the thrombolytic agent administered is 0.2 to 4 mg.

### Claim 5 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the total dose of the thrombolytic agent administered is 0.2 to 0.8 mg.

### Claim 6 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the total dose of the thrombolytic agent administered is 0.2 to 0.7 mg.

### Claim 7 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the total dose of the thrombolytic agent administered is 0.2 to 0.6 mg.

### Claim 8 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the thrombolytic agent is infused at a rate of 1 mg/hour or less.

### Claim 9 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the time over which the total dose is delivered is 1 hour or less.

### Claim 10 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the thrombolytic agent is recombinant tissue plasminogen activator (r-tPA) or urokinase.

### Claim 11 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein ultrasound is provided at a frequency of between 2-3 MHz.

### Claim 12 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein a maximum pulse power of ultrasound is 50 W.

### Claim 13 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the thrombolytic agent is delivered through a catheter that comprises a fluid delivery lumen and an inner core into which a plurality of ultrasound radiating members may be removably inserted and which is independent of the fluid delivery lumen, through which the thrombolytic agent is administered.

### Claim 14 (depends on 1)

The thrombolytic agent for use according to claim 1, wherein the thrombolytic agent is administered through 2 catheters simultaneously.

### Claim 15

A thrombolytic agent for use in a treatment of a thromboembolism, wherein the treatment comprises administering the thrombolytic agent directly to the thromboembolism in the presence of ultrasound, wherein a total dose of the thrombolytic agent administered is between 0.1 and 0.9 mg and the time over which the total dose of the thrombolytic agent is delivered is 1 hour or less.

### Claim 16 (depends on 15)

The thrombolytic agent for use according to claim 15, wherein the thrombolytic agent is delivered as one or more bolus doses.

### Claim 17

A method for treating a thromboembolism, the method comprising:
administering a thrombolytic agent to a patient with a thromboembolism;
wherein administering the thrombolytic agent to the patient includes administering the thrombolytic agent directly to the thromboembolism in the presence of ultrasound;
wherein a total dose of the thrombolytic agent is between 0.1 and 12 mg;
wherein the total dose is administered as one or more bolus doses of between 0.1 and 0.9 mg; and
wherein the time over which the total dose is delivered is 6 hours or less.

### Claim 18 (depends on 17)

The method of claim 17, wherein the thrombolytic agent includes recombinant tissue plasminogen activator (r-tPA).

### Claim 19 (depends on 17)

The method of claim 17, wherein the thrombolytic agent includes urokinase.

### Claim 20 (depends on 17)

The method of claim 17, wherein the thrombolytic agent is delivered through a catheter that comprises a fluid delivery lumen and an inner core into which a plurality of ultrasound radiating members may be removably inserted and which is independent of the fluid delivery lumen, through which the thrombolytic agent is administered.
